ArticleBiochemistry (Moscow) Supplement. Series B, Biomedical chemistry2022
The Effect of Methylene Blue and Its Metabolite-Azure I-on Bioenergetic Parameters of Intact Mouse Brain Mitochondria.
Article in Biochemistry (Moscow) Supplement. Series B, Biomedical chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 7 citations in OpenAlex.
- Methylene blue in the critical care setting.World journal of critical care medicine · 2025Review
- Methylene blue at recommended concentrations alters metabolism in early zebrafish development.Communications biology · 2025Article
- In Vitro Methylene Blue and Carboplatin Combination Triggers Ovarian Cancer Cells Death.International journal of molecular sciences · 2024Article
- The Influence of Pore-Forming Diluents on Porous Structure, Thermal and Sorption Properties of the Divinylbenzene and Glycidyl Methacrylate Copolymers.Materials (Basel, Switzerland) · 2024Article
- Possible Treatment of Topical Steroid Withdrawal with Methylene Blue Case Report: Implications for Mitochondrial Pathology.Case reports in dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methylene blue, a phenothiazine dye, that is widely used in medicine and is under clinical trials as an agent for treatment of Alzheimer's disease. One of the factors of the unique therapeutic effect of methylene blue is its redox properties, allowing implementation of alternative electron transport: the dye accepts electrons from reducing equivalents in mitochondria and transfer them to other components of the respiratory chain or molecular oxygen. Azure I, an
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.